Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis
- 30 March 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (Supplement), S680-S687
- https://doi.org/10.1093/infdis/jiz683
Abstract
Background Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection (ALRI) in young children aged <5 years. Methods We aimed to identify the global inpatient and outpatient cost of management of RSV-ALRI in young children to assist health policy makers in making decisions related to resource allocation for interventions to reduce severe morbidity and mortality from RSV in this age group. We searched 3 electronic databases including Global Health, Medline, and EMBASE for studies reporting cost data on RSV management in children under 60 months from 2000 to 2017. Unpublished data on the management cost of RSV episodes were collected through collaboration with an international working group (RSV GEN) and claim databases. Results We identified 41 studies reporting data from year 1987 to 2017, mainly from Europe, North America, and Australia, covering the management of a total of 365 828 RSV disease episodes. The average cost per episode was €3452 (95% confidence interval [CI], 3265–3639) and €299 (95% CI, 295–303) for inpatient and outpatient management without follow-up, and it increased to €8591(95% CI, 8489–8692) and €2191 (95% CI, 2190–2192), respectively, with follow-up to 2 years after the initial event. Conclusions Known risk factors (early and late preterm birth, congenital heart disease, chronic lung disease, intensive care unit admission, and ventilator use) were associated with €4160 (95% CI, 3237–5082) increased cost of hospitalization. The global cost of inpatient and outpatient RSV ALRI management in young children in 2017 was estimated to be approximately €4.82 billion (95% CI, 3.47–7.93), 65% of these in developing countries and 55% of global costs accounted for by hospitalization. We have demonstrated that RSV imposed a substantial economic burden on health systems, governments, and the society.Keywords
Funding Information
- Innovative Medicines Initiative 2 Joint Undertaking (116019)
- European Union’s Horizon 2020 research and innovation programme and EFPIA
- Sanofi Pastuer
This publication has 40 references indexed in Scilit:
- A comparison of healthcare resource use for rotavirus and RSV between vulnerable children with co-morbidities and healthy children: a case control studyJournal of Medical Economics, 2013
- Epidemiological Study of Hospitalization Associated With Respiratory Syncytial Virus Infection in Taiwanese Children Between 2004 and 2007Journal of the Formosan Medical Association, 2011
- Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infantsCurrent Medical Research and Opinion, 2010
- Healthcare costs within a year of respiratory syncytial virus among medicaid infantsPediatric Pulmonology, 2010
- Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, JordanScandinavian Journal of Infectious Diseases, 2010
- Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of lifeJournal of Medical Economics, 2009
- Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attentionCurrent Medical Research and Opinion, 2009
- The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged childrenRespiratory Research, 2008
- Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in GermanyEuropean Journal of Pediatrics, 2005
- Economic Impact of Respiratory Syncytial Virus-Related Illness in the USPharmacoEconomics, 2004